Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1996-6-7
|
pubmed:abstractText |
Penicillin therapy has considerably reduced the occurrence of serious late complications of streptococcal pharyngotonsillitis. However, treatment failure with this antibiotic is currently reported in up to 30% of the cases. Beta-lactamase production by the commensal flora of the tonsils, and poor compliance of patients have been implicated as the main causes of treatment failure. Cefetamet pivoxil is a new oral cephalosporin with a twice daily dosage and striking stability against beta-lactamases. We are conducting a prospective, randomized study in 120 children, comparing the efficacy of cefetamet pivoxil 10 mg/kg bid for 5 and 10 days and phenoxymethyl penicillin 25,000 U/kg tid for 10 days in the treatment of group A beta-hemolytic streptococcus (GABHS) pharyngotonsillitis. Children are enrolled after the positive culture of a throat swab and randomly assigned to one of the three groups. A follow-up check-up is performed at the end of the therapy (clinical check-up) and 3 to 5 days later (bacteriological check-up). The preliminary analysis of 55 cases shows that in 88.9%, 100% and 87.5% of children GABHS was eradicated by 5 days or 10 days of cefetamet pivoxil, or 10 days of penicillin respectively (p = NS). Side effect were mild and transient in cefetamet pivoxil-treated patients, but required cessation of treatment in 2 children treated with penicillin. These results suggest that cefetamet pivoxil therapy for 5 days eradicates GABHS from the throat in streptococcal pharyngotonsillitis as efficiently as cefetamet pivoxil or phenoxymethyl penicillin for 10 days.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Ceftizoxime,
http://linkedlifedata.com/resource/pubmed/chemical/Cephalosporins,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillin V,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillins,
http://linkedlifedata.com/resource/pubmed/chemical/cefetamet pivoxyl
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1120-009X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
21-4
|
pubmed:dateRevised |
2009-8-4
|
pubmed:meshHeading |
pubmed-meshheading:8618109-Ceftizoxime,
pubmed-meshheading:8618109-Cephalosporins,
pubmed-meshheading:8618109-Child,
pubmed-meshheading:8618109-Child, Preschool,
pubmed-meshheading:8618109-Female,
pubmed-meshheading:8618109-Humans,
pubmed-meshheading:8618109-Infant,
pubmed-meshheading:8618109-Male,
pubmed-meshheading:8618109-Penicillin V,
pubmed-meshheading:8618109-Penicillins,
pubmed-meshheading:8618109-Pharyngitis,
pubmed-meshheading:8618109-Prospective Studies,
pubmed-meshheading:8618109-Streptococcal Infections,
pubmed-meshheading:8618109-Streptococcus pyogenes,
pubmed-meshheading:8618109-Tonsillitis
|
pubmed:year |
1995
|
pubmed:articleTitle |
Cefetamet pivoxil in the treatment of pharyngotonsillitis due to group A beta-hemolytic streptococci: preliminary report.
|
pubmed:affiliation |
Department of Pediatrics, Hôpital Cantonal Universitaire, Geneva, Switzerland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|